Skip to main content
×
Home
    • Aa
    • Aa

Drug resistance maps to guide intermittent preventive treatment of malaria in African infants

  • INBARANI NAIDOO (a1) (a2) and CALLY ROPER (a1)
Summary
SUMMARY

Intermittent preventive treatment of infants (IPTi) with sulphadoxine pyrimethamine (SP) is recommended as an additional malaria control intervention in high transmission areas of sub-Saharan Africa, provided its protective efficacy is not compromised by SP resistance. A significant obstacle in implementing SP-IPTi, is in establishing the degree of resistance in an area. Since SP monotherapy is discontinued, no contemporary measures of in vivo efficacy can be made, so the World Health Organisation has recommended a cut-off based upon molecular markers, stating that SP-IPTi should not be implemented when the prevalence of the dhps 540E mutation among infections exceeds 50%. We created a geo-referenced database of SP resistance markers in Africa from published literature. By selecting surveys of malaria infected blood samples conducted since 2004 we have mapped the contemporary prevalence of dhps 540E. Additional maps are freely available in interactive form at http://www.drugresistancemaps.org/ipti/. Eight countries in East Africa are classified as unsuitable for SP-IPTi when data are considered at a national level. Fourteen countries in Central and West Africa were classified as suitable while seven countries had no available contemporary data to guide policy. There are clear deficiencies in molecular surveillance data coverage. We discuss requirements for ongoing surveillance of SP resistance markers in support of the use of SP-IPTi.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Drug resistance maps to guide intermittent preventive treatment of malaria in African infants
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Drug resistance maps to guide intermittent preventive treatment of malaria in African infants
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Drug resistance maps to guide intermittent preventive treatment of malaria in African infants
      Available formats
      ×
Copyright
The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence . The written permission of Cambridge University Press must be obtained for commercial re-use.
Corresponding author
*Corresponding author: London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, United Kingdom Tel.: +44 (0) 207 927 2331 Fax: +44 (0) 207 636 8739. Email: cally.roper@lshtm.ac.uk
References
Hide All
Alifrangis M., Lusingu J. P., Mmbando B., Dalgaard M. B., Vestergaard L. S., Ishengoma D., Khalil I. F., Theander T. G., Lemnge M. M. and Bygbjerg I. C. (2009). Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. American Journal of Tropical Medicine and Hygiene 80, 523527.
Alker A. P., Mwapasa V., Purfield A., Rogerson S. J., Molyneux M. E., Kamwendo D. D., Tadesse E., Chaluluka E. and Meshnick S. R. (2005). Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrobial Agents and Chemotherapy 49, 39193921.
Andriantsoanirina V., Ratsimbasoa A., Bouchier C., Jahevitra M., Rabearimanana S., Radrianjafy R., Andrianaranjaka V., Randriantsoa T., Rason M. A., Tichit M., Rabarijaona L. P., Mercereau-Puijalon O., Durand R. and Menard D. (2009). Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrobial Agents and Chemotherapy 53, 45884597.
Aponte J. J., Schellenberg D., Egan A., Breckenridge A., Carneiro I., Critchley J., Danquah I., Dodoo A., Kobbe R., Lell B., May J., Premji Z., Sanz S., Sevene E., Soulaymani-Becheikh R., Winstanley P., Adjei S., Anemana S., Chandramohan D., Issifou S., Mockenhaupt F., Owusu-Agyei S., Greenwood B., Grobusch M. P., Kremsner P. G., Macete E., Mshinda H., Newman R. D., Slutsker L., Tanner M., Alonso P. and Menendez C. (2009). Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374, 15331542.
Bell D. J., Nyirongo S. K., Mukaka M., Zijlstra E. E., Plowe C. V., Molyneux M. E., Ward S. A. and Winstanley P. A. (2008). Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS ONE 3, e1578.
Bonizzoni M., Afrane Y., Baliraine F. N., Amenya D. A., Githeko A. K. and Yan G. (2009). Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western Kenya. Infection, Genetics and Evolution 9, 806812.
Bridges D. J., Molyneux M. and Nkhoma S. (2009). Low level genotypic chloroquine resistance near Malawi's northern border with Tanzania. Tropical Medicine and International Health 14, 10931096.
Brooks D. R., Wang P., Read M., Watkins W. M., Sims P. F. and Hyde J. E. (1994). Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. European Journal of Biochemistry 224, 397405.
Bwijo B., Kaneko A., Takechi M., Zungu I. L., Moriyama Y., Lum J. K., Tsukahara T., Mita T., Takahashi N., Bergqvist Y., Bjorkman A. and Kobayakawa T. (2003). High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta Tropica 85, 363373.
Certain L. K., Briceno M., Kiara S. M., Nzila A. M., Watkins W. M. and Sibley C. H. (2008). Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987–2006. Journal of Infectious diseases 197, 17431751.
Chandramohan D., Owusu-Agyei S., Carneiro I., Awine T., Amponsa-Achiano K., Mensah N., Jaffar S., Baiden R., Hodgson A., Binka F. and Greenwood B. (2005). Cluster randomised trial of intermittent preventive treatment of malaria in infants in area of high, seasonal transmission in Ghana. British Medical Journal 331, 727733.
Cowman A. F., Morry M. J., Biggs B. A., Cross G. A. and Foote S. J. (1988). Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proceedings of the National Academy of Sciences, USA 85, 91099113.
Dicko A., Sagara I., Djimde A. A., Toure S. O., Traore M., Dama S., Diallo A. I., Barry A., Dicko M., Coulibaly O. M., Rogier C., De Sousa A. and Doumbo O. K. (2010). Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malaria Journal 9, 9.
Djimde A. A., Fofana B., Sagara I., Sidibe B., Toure S., Dembele D., Dama S., Ouologuem D., Dicko A. and Doumbo O. K. (2008). Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. American Journal of Tropical Medicine and Hygiene 78, 455461.
Dunyo S., Ord R., Hallett R., Jawara M., Walraven G., Mesa E., Coleman R., Sowe M., Alexander N., Targett G. A., Pinder M. and Sutherland C. J. (2006). Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clinical Trials 1, e14.
Enevold A., Nkya W. M., Theisen M., Vestergaard L. S., Jensen A. T., Staalsoe T., Theander T. G., Bygbjerg I. C. and Alifrangis M. (2007). Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malaria Journal 6, 153.
Enosse S., Magnussen P., Abacassamo F., Gomez-Olive X., Ronn A. M., Thompson R. and Alifrangis M. (2008). Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malaria Journal 7, 115.
Fernandes N., Figueiredo P., Do Rosario V. E. and Cravo P. (2007). Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant. Malaria Journal 6, 35.
Francis D., Nsobya S. L., Talisuna A., Yeka A., Kamya M. R., Machekano R., Dokomajilar C., Rosenthal P. J. and Dorsey G. (2006). Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. Journal of Infectious Diseases 193, 978986.
Gebru-Woldearegai T., Hailu A., Grobusch M. P. and Kun J. F. (2005). Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. American Journal of Tropical Medicine and Hygiene 73, 11311134.
Gesase S., Gosling R. D., Hashim R., Ord R., Naidoo I., Madebe R., Mosha J. F., Joho A., Mandia V., Mrema H., Mapunda E., Savael Z., Lemnge M., Mosha F. W., Greenwood B., Roper C. and Chandramohan D. (2009). High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE 4, e4569.
Gosling R. D., Gesase S., Mosha J. F., Carneiro I., Hashim R., Lemnge M., Mosha F. W., Greenwood B. and Chandramohan D. (2009). Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374, 15211532.
Griffin J. T., Cairns M., Ghani A. C., Roper C., Schellenberg D., Carneiro I., Newman R. D., Grobusch M. P., Greenwood B., Chandramohan D. and Gosling R. D. (2010). Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. PLoS ONE 5, e12618.
Grobusch M. P., Egan A., Gosling R. D. and Newman R. D. (2007 a). Intermittent preventive therapy for malaria: progress and future directions. Current Opinion in Infectious Diseases 20, 613620.
Grobusch M. P., Lell B., Schwarz N. G., Gabor J., Dornemann J., Potschke M., Oyakhirome S., Kiessling G. C., Necek M., Langin M. U., Klein Klouwenberg P., Klopfer A., Naumann B., Altun H., Agnandji S. T., Goesch J., Decker M., Salazar C. L., Supan C., Kombila D. U., Borchert L., Koster K. B., Pongratz P., Adegnika A. A., Glasenapp I., Issifou S. and Kremsner P. G. (2007 b). Intermittent preventive treatment against malaria in infants in Gabon – a randomized, double-blind, placebo-controlled trial. Journal of Infectious diseases 196, 15951602.
Harrington W. E., Mutabingwa T. K., Muehlenbachs A., Sorensen B., Bolla M. C., Fried M. and Duffy P. E. (2009). Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proceedings of the National Academy, USA 106, 90279032.
Karema C., Imwong M., Fanello C. I., Stepniewska K., Uwimana A., Nakeesathit S., Dondorp A., Day N. P. and White N. J. (2010). Molecular correlates of high level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrobial Agents and Chemotherapy 54, 477483.
Kobbe R., Kreuzberg C., Adjei S., Thompson B., Langefeld I., Thompson P. A., Abruquah H. H., Kreuels B., Ayim M., Busch W., Marks F., Amoah K., Opoku E., Meyer C. G., Adjei O. and May J. (2007). A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clinical Infectious Diseases 45, 1625.
Kublin J. G., Dzinjalamala F. K., Kamwendo D. D., Malkin E. M., Cortese J. F., Martino L. M., Mukadam R. A., Rogerson S. J., Lescano A. G., Molyneux M. E., Winstanley P. A., Chimpeni P., Taylor T. E. and Plowe C. V. (2002). Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Journal of Infectious Diseases 185, 380388.
Kun J. F., Lehman L. G., Lell B., Schmidt-Ott R. and Kremsner P. G. (1999). Low-dose treatment with sulfadoxine-pyrimethamine combinations selects for drug-resistant Plasmodium falciparum strains. Antimicrobial Agents and Chemotherapy 43, 22052208.
Lozovsky E. R., Chookajorn T., Brown K. M., Imwong M., Shaw P. J., Kamchonwongpaisan S., Neafsey D. E., Weinreich D. M. and Hartl D. L. (2009). Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proceedings of the National Academy of Sciences, USA 106, 1202512030.
Lynch C., Pearce R., Pota H., Cox J., Abeku T. A., Rwakimari J., Naidoo I., Tibenderana J. and Roper C. (2008). Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. Journal of Infectious Diseases 197, 15981604.
Macete E., Aide P., Aponte J. J., Sanz S., Mandomando I., Espasa M., Sigauque B., Dobano C., Mabunda S., Dgedge M., Alonso P. and Menendez C. (2006). Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. Journal of Infectious Diseases 194, 276285.
Maiga O., Djimde A. A., Hubert V., Renard E., Aubouy A., Kironde F., Nsimba B., Koram K., Doumbo O. K., Le Bras J. and Clain J. (2007). A shared Asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. Journal of Infectious Diseases 196, 165172.
Malisa A. L., Pearce R. J., Abdulla S., Mshinda H., Kachur P. S., Bloland P. and Roper C. (2010). Drug coverage in treatment of malaria and the consequences for resistance evolution – evidence from the use of sulphadoxine/pyrimethamine. Malaria Journal 9, 190.
Marks F., Evans J., Meyer C. G., Browne E. N., Flessner C., Von Kalckreuth V., Eggelte T. A., Horstmann R. D. and May J. (2005). High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrobial Agents and Chemotherapy 49, 11011105.
McCollum A. M., Poe A. C., Hamel M., Huber C., Zhou Z., Shi Y. P., Ouma P., Vulule J., Bloland P., Slutsker L., Barnwell J. W., Udhayakumar V. and Escalante A. A. (2006). Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. Journal of Infectious Diseases 194, 189197.
Menegon M., Pearce R. J., Inojosa W. O., Pisani V., Abel P. M., Matondo A., Bisoffi Z., Majori G., Ord R., Warhurst D. C., Roper C. and Severini C. (2009). Monitoring for multidrug-resistant Plasmodium falciparum isolates and analysis of pyrimethamine resistance evolution in Uige province, Angola. Tropical Medicine and International Health 14, 12511257.
Mkulama M. A., Chishimba S., Sikalima J., Rouse P., Thuma P. E. and Mharakurwa S. (2008). Escalating Plasmodium falciparum antifolate drug resistance mutations in Macha, rural Zambia. Malaria Journal 7, 87.
Mockenhaupt F. P., Reither K., Zanger P., Roepcke F., Danquah I., Saad E., Ziniel P., Dzisi S. Y., Frempong M., Agana-Nsiire P., Amoo-Sakyi F., Otchwemah R., Cramer J. P., Anemana S. D., Dietz E. and Bienzle U. (2007). Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrobial Agents and Chemotherapy 51, 32733281.
Mockenhaupt F. P., Teun Bousema J., Eggelte T. A., Schreiber J., Ehrhardt S., Wassilew N., Otchwemah R. N., Sauerwein R. W. and Bienzle U. (2005). Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Tropical Medicine and International Health 10, 901908.
Naidoo I. and Roper C. (2010). Following the path of most resistance: dhps K540E dispersal in African Plasmodium falciparum. Trends in Parasitology 26, 447456.
Ndounga M., Tahar R., Basco L. K., Casimiro P. N., Malonga D. A. and Ntoumi F. (2007). Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville, Congo. Tropical Medicine and International Health 12, 11641171.
Nkhoma S., Molyneux M. and Ward S. (2007). Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Tropica 102, 138142.
Ochong E., Bell D. J., Johnson D. J., D'alessandro U., Mulenga M., Muangnoicharoen S., Van Geertruyden J. P., Winstanley P. A., Bray P. G., Ward S. A. and Owen A. (2008). Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure. Antimicrobial Agents and Chemotherapy 52, 38833888.
Omar S. A., Adagu I. S. and Warhurst D. C. (2001). Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 315319.
Pearce R. J., Pota H., Evehe M. S., Ba El H., Mombo-Ngoma G., Malisa A. L., Ord R., Inojosa W., Matondo A., Diallo D. A., Mbacham W., Van Den Broek I. V., Swarthout T. D., Getachew A., Dejene S., Grobusch M. P., Njie F., Dunyo S., Kweku M., Owusu-Agyei S., Chandramohan D., Bonnet M., Guthmann J. P., Clarke S., Barnes K. I., Streat E., Katokele S. T., Uusiku P., Agboghoroma C. O., Elegba O. Y., Cisse B., Ie A. E., Giha H. A., Kachur S. P., Lynch C., Rwakimari J. B., Chanda P., Hawela M., Sharp B., Naidoo I. and Roper C. (2009). Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Medicine 6, e1000055.
Peterson D. S., Walliker D. and Wellems T. E. (1988). Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proceedings of the National Academy of Sciences, USA 85, 91149118.
Plowe C. V., Cortese J. F., Djimde A., Nwanyanwu O. C., Watkins W. M., Winstanley P. A., Estrada-Franco J. G., Mollinedo R. E., Avila J. C., Cespedes J. L., Carter D. and Doumbo O. K. (1997). Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. Journal of Infectious diseases 176, 15901596.
Raman J., Little F., Roper C., Kleinschmidt I., Cassam Y., Maharaj R. and Barnes K. I. (2010). Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. American Journal of Tropical Medicine and Hygiene 82, 788794.
Raman J., Sharp B., Kleinschmidt I., Roper C., Streat E., Kelly V. and Barnes K. I. (2008). Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique. American Journal of Tropical Medicine and Hygiene 78, 256261.
Rogier C., Pradines B., Bogreau H., Koeck J. L., Kamil M. A. and Mercereau-Puijalon O. (2005). Malaria epidemic and drug resistance, Djibouti. Emerging Infectious Diseases 11, 317321.
Roper C., Pearce R., Nair S., Sharp B., Nosten F. and Anderson T. (2004). Intercontinental spread of pyrimethamine-resistant malaria. Science 305, 1124.
Schellenberg D., Menendez C., Aponte J. J., Kahigwa E., Tanner M., Mshinda H. and Alonso P. (2005). Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 365, 14811483.
Schellenberg D., Menendez C., Kahigwa E., Aponte J., Vidal J., Tanner M., Mshinda H. and Alonso P. (2001). Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357, 14711477.
Schunk M., Kumma W. P., Miranda I. B., Osman M. E., Roewer S., Alano A., Loscher T., Bienzle U. and Mockenhaupt F. P. (2006). High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. In Malaria Journal 5, 54.
Staedke S. G., Sendagire H., Lamola S., Kamya M. R., Dorsey G. and Rosenthal P. J. (2004). Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Tropical Medicine and International Health 9, 624629.
Tekete M., Djimde A. A., Beavogui A. H., Maiga H., Sagara I., Fofana B., Ouologuem D., Dama S., Kone A., Dembele D., Wele M., Dicko A. and Doumbo O. K. (2009). Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali. Malaria Journal 8, 34.
Thera M. A., Sehdev P. S., Coulibaly D., Traore K., Garba M. N., Cissoko Y., Kone A., Guindo A., Dicko A., Beavogui A. H., Djimde A. A., Lyke K. E., Diallo D. A., Doumbo O. K. and Plowe C. V. (2005). Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. Journal of Infectious Diseases 192, 18231829.
Triglia T. and Cowman A. F. (1994). Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proceedings of the National Academy of Sciences, USA 91, 71497153.
Triglia T., Menting J. G., Wilson C. and Cowman A. F. (1997). Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proceedings of the National Academy of Sciences, USA 94, 1394413949.
Wang P., Lee C. S., Bayoumi R., Djimde A., Doumbo O., Swedberg G., Dao L. D., Mshinda H., Tanner M., Watkins W. M., Sims P. F. and Hyde J. E. (1997). Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Molecular and Biochemical Parasitology 89, 161177.
WHO (2009). Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi),Technical Expert Group on Preventive Chemotherapy.WHO TEG IPTi Report April 2009. World Health Organisation pp. 111.
Zhong D., Afrane Y., Githeko A., Cui L., Menge D. M. and Yan G. (2008). Molecular epidemiology of drug-resistant malaria in western Kenya highlands. In BMC Infectious Diseases 8, 105.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Parasitology
  • ISSN: 0031-1820
  • EISSN: 1469-8161
  • URL: /core/journals/parasitology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
WORD
Supplementary Materials

Naidoo Supplementary Materials
Supplementary Information: dhps 581 bibliography

 Word (59 KB)
59 KB
WORD
Supplementary Materials

Naidoo Supplementary Materials
S1: Supplementary Information: dhps 540 bibliography

 Word (93 KB)
93 KB
WORD
Supplementary Materials

Naidoo Supplementary Materials
Supplementary Information: dhfr 164 bibliography

 Word (64 KB)
64 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 3
Total number of PDF views: 134 *
Loading metrics...

Abstract views

Total abstract views: 169 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd October 2017. This data will be updated every 24 hours.